Amgen Inc   (AMGN)
Other Ticker:  
Price: $267.2800 $-2.72 -1.007%
Day's High: $269.3 Week Perf: -0.71 %
Day's Low: $ 266.17 30 Day Perf: -2.93 %
Volume (M): 2,140 52 Wk High: $ 329.72
Volume (M$): $ 572,006 52 Wk Avg: $262.21
Open: $268.77 52 Wk Low: $211.71

 Market Capitalization (Millions $) 143,741
 Shares Outstanding (Millions) 538
 Employees 24,200
 Revenues (TTM) (Millions $) 28,190
 Net Income (TTM) (Millions $) 6,717
 Cash Flow (TTM) (Millions $) 3,315
 Capital Exp. (TTM) (Millions $) 1,112

Amgen Inc
Amgen Inc.'Is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology. On July'15, 2002, Amgen acquired all of the outstanding common stock of Immunex Corporation ('Immunex') for stock and cash valued at $17.8'billion in a transaction accounted for as a business combination. Immunex was a leading biotechnology company dedicated to developing immune system science to protect human health. The acquisition has enhanced Amgen's strategic position within the biotechnology industry by strengthening and diversifying its (1)'product base and product pipeline in key therapeutic areas, and (2)'discovery research capabilities in proteins and antibodies.

The Company markets human therapeutic products in the areas of hematology, oncology, and inflammation. The Company's key products include EPOGEN' (Epoetin alfa), Aranesp' (darbepoetin alfa), Neulasta' (pegfilgrastim), NEUPOGEN' (Filgrastim), and ENBREL' (etanercept), which is marketed under a co-promotion agreement with Wyeth. The Company's other products include Kineret' (anakinra)'and Stemgen' (Ancestim).

EPOGEN' and Aranesp' stimulate the production of red blood cells. EPOGEN' is marketed in the United States for the treatment of anemia associated with chronic renal failure in patients on dialysis. Aranesp' is marketed in the United States, most countries in Europe, Australia, and New Zealand for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis. Aranesp' is also marketed in the United States for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. Aranesp' is marketed in Europe for the treatment of anemia in adult cancer patients with solid tumors receiving chemotherapy and for the treatment of chemotherapy-induced anemia in adult patients with non-myeloid malignancies.

Neulasta' and NEUPOGEN' selectively stimulate the production of neutrophils, one type of white blood cell. Neulasta' is marketed in the United States to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta' is marketed in most countries in Europe for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients with cytotoxic chemotherapy for malignancy. NEUPOGEN' is marketed in the United States, certain countries in Europe, Canada, and Australia for use in decreasing the incidence of infection in patients undergoing myelosuppressive chemotherapy. In addition, NEUPOGEN' is marketed in most of these countries for use in increasing neutrophil counts in various other treatment modalities.

ENBREL' blocks the biologic activity of tumor necrosis factor ('TNF') by competitively inhibiting TNF, a substance induced in response to inflammatory and immunological responses. ENBREL' is marketed in the United States for reducing the signs and symptoms, improving physical function, and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis; and for reducing the signs and symptoms and inhibiting the progression of structural damage in patients with psoriatic arthritis. In addition, ENBREL is approved for reducing the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying medicines; and to treat the signs and symptoms in patients with active ankylosing spondylitis.

The Company maintains a sales and marketing force in the United States, Europe, Canada, Australia, and New Zealand. In addition, Amgen has entered into licensing and/or co-promotion agreements to market certain of its products including Aranesp', Neulasta', NEUPOGEN', and ENBREL' in certain geographic areas outside of the United States.

The Company focuses its research and development ('R&D') efforts on human therapeutics delivered in the form of proteins, monoclonal antibodies, and small molecules in the areas of hematology, oncology, inflammation, metabolic and bone disorders, and neuroscience. The Company has research facilities in the United States, and has clinical development staff in the United States, Europe, Canada, Australia, and Japan. In addition to internal R&D efforts, the Company has acquired certain product and technology rights and has established R&D collaborations.

The Company manufactures EPOGEN', Aranesp', Neulasta', NEUPOGEN', and ENBREL'. Amgen operates commercial manufacturing facilities located in the United States, Puerto Rico, and a packaging and distribution center in the Netherlands. Additional supply of ENBREL' is produced by our contract manufacturer, Boehringer Ingelheim Pharma KG ('BI'Pharma').

Any products or technologies that are directly or indirectly successful in addressing anemia could negatively impact the market for EPOGEN' and Aranesp'. Aranesp' directly competes with other currently marketed products which treat anemia, including EPOGEN' and the recombinant human erythropoietin product marketed by Johnson'& Johnson. Aventis Pharmaceuticals Inc. ('Aventis') is developing gene-activated erythropoietin for the treatment of anemia. Baxter International Inc. ('Baxter') is developing epoetin omega for the treatment of anemia. Roche is developing a pegylated erythropoietin product for the treatment of anemia.

Any products or technologies that are directly or indirectly successful in addressing anemia associated with chemotherapy could negatively impact the market for Aranesp'. In the United States, Aranesp' directly competes with other currently marketed products which treat anemia associated with chemotherapy, including the recombinant human erythropoietin product marketed by Johnson'& Johnson. In Europe, Aranesp' directly competes with other erythropoietin products marketed by Ortho Biotech/Janssen-Cilag/Johnson'& Johnson and Roche in the oncology setting.

Chugai Pharmaceuticals Co., Ltd. ('Chugai') markets a G-CSF product in Japan as an adjunct to chemotherapy and as a treatment for bone marrow transplant ('BMT') patients. Chugai and Aventis market a G-CSF product in certain EU countries as an adjunct to chemotherapy and as a treatment in BMT settings. Chugai, through its licensee, AMRAD, markets this G-CSF product in Australia as an adjunct to chemotherapy and as a treatment for BMT patients. Under an agreement with Amgen, Chugai is precluded from selling its G-CSF product in the United States, Canada, and Mexico.

ENBREL' and PEG-sTNF-R1 could face competition in some circumstances from a number of companies developing or marketing rheumatoid arthritis and psoriatic arthritis treatments. Current anti-arthritic treatments include generic methotrexate and other products marketed by, among others, Centocor, Inc./Johnson'& Johnson, Abbott Laboratories ('Abbott'), Merck, Pfizer, Novartis, Aventis, and Sanofi-Synth'labo. In addition, a number of companies have cytokine inhibitors in development including GlaxoSmithKline, Pfizer, and Taisho Pharmaceutical Co., Ltd. Amgen is currently developing ENBREL' for the treatment of psoriasis. If ENBREL' is approved for this indication, it may compete with products marketed by Biogen, Genentech, and Johnson'& Johnson.

SensiparTM could face competition from products currently marketed by Abbott, Bone Care International, Inc., Genzyme Corporation, and Roche which treat secondary HPT. In addition, another product to treat HPT is currently being developed by Chugai.

The GDNF program could face competition from a deep brain stimulation device currently marketed by Medtronic Inc.

   Company Address: One Amgen Center Drive Thousand Oaks 91320 CA
   Company Phone Number: 447-1000   Stock Exchange / Ticker: NASDAQ AMGN

Customers Net Income fell by AMGN's Customers Net Profit Margin fell to

-8.7 %

2.6 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
BIIB   -3.3%    
ABBV   -4.43%    
ABT   -1.28%    
BMY   -5.52%    
JNJ   -2.68%    
MRK   -0.65%    
• View Complete Report

Amgen Inc

Energetic in Double Digits: Amgen Inc Outperforms Peers with a Substantial Top-line Rise Amid Recent Fiscal Period

Amgen Inc's latest financial report for the fourth quarter of 2023 has shown a mixed bag of results, with revenue increasing significantly but earnings per share plummeting. The company reported a 19.842% increase in revenue to $8.20 billion, outperforming many of its counterparts in the Biotechnology & Pharmaceuticals sector. However, earnings per share dropped by -52.98% to $1.42 per share, reflecting a challenging period for the company.
One of the key factors contributing to the decrease in earnings per share was the rise in inventories and supplies, which increased to $9,518.0 million. This buildup in inventories may indicate a shift in focus towards improving sales, as the company seeks to meet rising demand. Additionally, the increase in accounts receivable to $7,268.0 million suggests that sales numbers have been strong, further supporting the company's efforts to drive revenue growth.

Amgen Inc

Despite Increased Demand, Amgen Inc. Faces Declining Earnings in Q3 2023

Amgen Inc. (AMGN) announced its financial results for the third quarter closing on September 30, 2023. The company reported declining earnings per share (EPS) despite increased revenue. Revenue rose by 3.773% to $6.90 billion compared to $6.65 billion in the same period last year, while income fell by 19.1% to $3.22 per share. In the comparable three months of the previous year, the income per share was $3.98.
To assess Amgen Inc.'s performance in the third quarter of 2023, it is important to consider the Biotechnology & Pharmaceuticals industry as a whole. In comparison to its peers, Amgen Inc. fell short, as the industry witnessed top-line growth of 28.59% from the third quarter of 2022. In the prior reporting season, Amgen Inc. recorded revenue of $6.99 billion and a bottom line of $2.57 per share. The bottom line of $1,730.000 million in the fiscal third quarter of 2023 decreased by 19.27% from $2,143.000 million in the corresponding period a year ago.

Amgen Inc

Amgen Inc's Q2 Revenue Soars, Outpacing EPS Growth for Fiscal Period Ending June 2023

Amgen Inc: Accelerated Revenue Growth and Shifting Focus on Sales
Amgen Inc, a biotechnology company specializing in the development and manufacturing of innovative pharmaceutical products, recently released its second-quarter financial report for 2023. The report revealed that the company's revenue grew faster than its earnings per share (EPS) during this period. Despite modest growth in bottom-line earnings, Amgen reported a significant increase in revenue, making notable progress in increasing its net income.
During the second quarter of 2023, Amgen's revenue increased by 5.945% compared to the corresponding reporting season a year ago, reaching $6.99 billion. This growth is a positive sign for the company, as it indicates increasing demand and sales for its products. However, the bottom-line growth was relatively modest, with earnings per share growing by 4.9% to $2.57 per share.
In comparison to the preceding reporting period, Amgen experienced even more substantial advancements. Revenue advanced by 14.431% from $6.11 billion, demonstrating the company's continued growth and success. However, profit during this period plummeted by -51.33% from $5.28 per share. Despite this decline, Amgen managed to achieve a net income of $1,379.000 million, reflecting a 4.71% increase from the net earnings of $1,317.000 million reported in the same financial period a year ago.

Amgen Inc

Comparatively uneventful three months at Amgen Inc all along the most recent fiscal period

Investors take note - Biotechnology & Pharmaceuticals company Amgen Inc. reported its financials for the first quarter of 2023 earnings season, showing an impressive increase in earnings per share despite a decline in revenue. The company saw income per share soar by 97.01% to $5.28 per share, while revenue decreased by -2.132% to $6.11 billion year on year. These figures mark a notable improvement from the previous reporting period, where earnings per share was just $3.03 and revenue diminished by -10.733% to $6.84 billion.
The company also reported an impressive net income of $2,841,000 million in the first quarter, representing a robust increase of 92.48% compared to the same period last year when net earnings were $1,476,000 million. Despite a dip in operating margin to 31.47%, the company's net margin improved to 46.54%, indicating healthy performance.


Amgen Inc's Segments
United States
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Amgen Inc announced annual revenue outlook on

Earnings Outlook
Amgen Inc issued annual earnings guidance on

Geographic Revenue Dispersion
United States


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com